{"id":"NCT03009019","sponsor":"BioDelivery Sciences International","briefTitle":"Efficacy, Tolerability, and Safety of DFN-15","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2017-11","completion":"2019-05","firstPosted":"2017-01-04","resultsPosted":"2023-01-10","lastUpdate":"2023-01-10"},"enrollment":631,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Headache"],"interventions":[{"type":"DRUG","name":"DFN-15 Active","otherNames":["Celecoxib Oral Solution"]},{"type":"OTHER","name":"DFN-15 Placebo","otherNames":[]}],"arms":[{"label":"DFN-15 Active","type":"EXPERIMENTAL"},{"label":"DFN-15 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States","primaryOutcome":{"measure":"Percentage of Subjects Who Are Pain-free at 2 Hours Postdose (First Treated Double-blind Treatment Period)","timeFrame":"2 hours postdose","effectByArm":[{"arm":"DFN-15 Placebo (LOCF)","deltaMin":25.8,"sd":null},{"arm":"DFN-15 Active (LOCF)","deltaMin":32.9,"sd":null},{"arm":"DFN-15 Placebo (OC)","deltaMin":24.6,"sd":null},{"arm":"DFN-15 Active (OC)","deltaMin":32.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.075"},{"comp":"OG002 vs OG003","p":"0.055"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["34447267"],"seeAlso":["https://pubmed.ncbi.nlm.nih.gov/34447267/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":283},"commonTop":["Nausea"]}}